The clinicopathological significance of heparanase and basic fibroblast growth factor expressions in hepatocellular carcinoma

Clinical Cancer Research

Volumn 7, Issue 5, 2001, Pages 1299-1305

  El Assal, O N ^a   Yamanoi, A ^a   Ono, T ^a   Kohno, H ^a   Nagasue, N ^a  

^a SHIMANE UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; BLOOD CLOTTING FACTOR 8; HEPARANASE; MESSENGER RNA; MONOCLONAL ANTIBODY;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER INVASION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VASCULARIZATION;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; FIBROBLAST GROWTH FACTOR 2; GLUCURONIDASE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0034906312     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Heparanase: Breaking down barriers in tumors
2. Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis
3. Structural differences of heparan sulfates according to the tissue and the species of origin
4. Proteoglycans: Structures and interactions
5. Molecular architecture of basement membranes
6. Mammalian heparanase: Gene cloning, expression and function in tumor progression and metastasis
7. Glycosaminoglycans: Molecular properties, protein interactions and role in physiological processes
8. The role of proteoglycans in cell adhesion, migration and proliferation
9. The coordinated regulation of heparan sulfate, syndecans and cell behavior
10. Cell biology of arterial proteoglycans
11. Metastatic melanoma cell heparanase. Characterization of heparan sulfate degradation fragments produced by B16 melanoma endoglucuronidase
12. A rapid quantitative assay for the detection of mammalian heparanase activity
13. Heparan sulfate degradation: Relation to tumor invasive and metastatic properties of mouse B16 melanoma sublines
14. Heparanasestumor and tumor metastasis
15. Heparan sulfate endoglycosidase and metastatic potential in murine fibrosarcoma and melanoma
16. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: Possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver
17. Thymidine phosphorylase (platelet derived endothelial cell growth factor), microvessel density and clinical outcome in hepatocellular carcinoma
18. Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma
19. The FGF family of growth factors and oncogenes
20. Structural and functional diversity in the FGF receptor multigene family
21. Cell surface heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor
22. Heparin is required for cell-free binding of basic fibroblast growth factor to a soluble receptor and for mitogenesis of the whole cell
23. Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation
24. The extracellular regulation of growth factor action
25. Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2
26. Proposal of invasiveness score to predict recurrence and survival after curative hepatic resection for hepatocellular carcinoma
27. The biology of perlecan: The multifaceted heparan sulfate proteoglycan of basement membranes and pericellular matrices
28. Widespread expression of perlecan proteoglycan in basement membranes and extracellular matrices of human tissues as detected by a novel monoclonal antibody against domain III and by in situ hybridization
29. Proteoglycan of the extracellular environment: Clues from the gene and protein side offer novel perspectives in molecular diversity and function
30. Growth factors in the extracellular matrix
31. Heparin structure and interactions with basic fibroblast growth factor
32. Perlecan, basal lamina proteoglycan, promotes basic fibroblast growth factor-receptor binding, mitogenesis, and angiogenesis
33. Perlecan in human bone marrow: A growth-factor-presenting, but antiadhesive, extracellular matrix component for hematopoietic cells
34. A heparin-binding angiogenic protein-basic fibroblast growth factor is stored within basement membrane
35. The vascular endothelial growth factor (VEGF) isoforms: Differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF
36. Interaction of hepatocyte growth factor with heparan sulfate, elucidation of the major heparan sulfate structural determinants
37. Hairpin loop and second kringle domain are essential sites for heparin binding and biological activity of hepatocyte growth factor
38. Compartmentalization of PDGF on extracellular binding sites dependent on exon-6-encoded sequences
39. Fibroblast growth factor 1 and fibroblast growth factor 2 immunoreactivity in gastrointestinal tumors
40. Upregulation of basic fibroblast growth factor in breast carcinoma and its relationship to vascular density, estrogen receptor, epidermal growth factor receptor and survival
41. Alternations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGR-1 in human prostatic cancer
42. Serum concentration of VEGF and b-FGF in renal cell, prostate and urinary bladder carcinomas
43. Expression of basic fibroblast growth factor protein and its down-regulation by interferons in head and neck cancer
44. Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor
45. Basic fibroblast growth factor induces angiogenesis in vitro
46. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro
47. Expression of vascular endothelial growth factor in human hepatocellular carcinoma